Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Triple-Negative Breast Carcinoma”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03546686
What this trial is testing

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
University of Texas Southwestern Medical Center 51
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Testing effectiveness (Phase 2)Ended earlyNCT03979508
What this trial is testing

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+15 more
Mayo Clinic 26
Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing

Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50
Testing effectiveness (Phase 2)Study completedNCT00861705
What this trial is testing

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Male Breast CarcinomaStage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7+2 more
National Cancer Institute (NCI) 454
Not applicableLooking for participantsNCT06349642
What this trial is testing

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Who this might be right for
Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical Carcinoma+24 more
Mayo Clinic 324
Testing effectiveness (Phase 2)Ended earlyNCT04434560
What this trial is testing

Neoadjuvant Immunotherapy in Brain Metastases

Who this might be right for
Brain Metastases, Adult
Sarah Sammons, MD 1
Testing effectiveness (Phase 2)Study completedNCT00951054
What this trial is testing

NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 61
Large-scale testing (Phase 3)Not Yet RecruitingNCT04301739
What this trial is testing

To Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer
Shanghai Henlius Biotech 522
Testing effectiveness (Phase 2)Looking for participantsNCT03815890
What this trial is testing

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05821686
What this trial is testing

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Nova Scotia Health Authority 10